NASDAQ:ATEC - Alphatec Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.64 -0.06 (-2.22 %) (As of 03/24/2019 07:00 AM ET)Previous Close$2.64Today's Range$2.52 - $2.7052-Week Range$1.18 - $4.21Volume339,987 shsAverage Volume747,830 shsMarket Capitalization$114.07 millionP/E RatioN/ADividend YieldN/ABeta1.14 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. It also provides cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, and Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate; and interbody Systems, such as Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer. In addition, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California. Receive ATEC News and Ratings via Email Sign-up to receive the latest news and ratings for ATEC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ATEC Previous Symbol CUSIP02081G10 CIK1350653 Webwww.alphatecspine.com Phone760-431-9286Debt Debt-to-Equity Ratio1.42 Current Ratio2.36 Quick Ratio1.48Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$91.69 million Price / Sales1.24 Cash Flow$0.1481 per share Price / Cash Flow17.83 Book Value($1.34) per share Price / Book-1.97Profitability EPS (Most Recent Fiscal Year)($0.58) Net Income$-42,460,000.00 Net Margins-31.60% Return on Equity-85.82% Return on Assets-17.82%Miscellaneous Employees138 Outstanding Shares43,210,000Market Cap$114.07 million Next Earnings Date5/9/2019 (Estimated) OptionableNot Optionable Alphatec (NASDAQ:ATEC) Frequently Asked Questions What is Alphatec's stock symbol? Alphatec trades on the NASDAQ under the ticker symbol "ATEC." How were Alphatec's earnings last quarter? Alphatec Holdings Inc (NASDAQ:ATEC) posted its quarterly earnings results on Thursday, March, 7th. The medical technology company reported ($0.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.03. The medical technology company had revenue of $25.34 million for the quarter. Alphatec had a negative return on equity of 85.82% and a negative net margin of 31.60%. View Alphatec's Earnings History. When is Alphatec's next earnings date? Alphatec is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Alphatec. What guidance has Alphatec issued on next quarter's earnings? Alphatec issued an update on its FY 2019 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $98-103 million, compared to the consensus revenue estimate of $99.95 million. What price target have analysts set for ATEC? 1 Wall Street analysts have issued 1 year price targets for Alphatec's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Alphatec's stock price to reach $4.00 in the next year. This suggests a possible upside of 51.5% from the stock's current price. View Analyst Price Targets for Alphatec. What is the consensus analysts' recommendation for Alphatec? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alphatec. What are Wall Street analysts saying about Alphatec stock? Here are some recent quotes from research analysts about Alphatec stock: 1. According to Zacks Investment Research, "Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company's principal product offering includes a variety of spinal implant products and systems consisted of components, such as spine screws and rods, spinal spacers, plates, and various biologics offerings. Alphatec Holdings, Inc. is headquartered in Carlsbad, California. " (3/22/2019) 2. HC Wainwright analysts commented, "We are maintaining our Buy rating of ATEC and our 12-month price target of $4.00 per diluted share. We derive our price target based on: 1) an EV-to-sales multiple analysis assuming 10% discount rate and using a 3.0x multiple on projected 2025 sales of $244M; and 2) a discounted cash flow analysis using the projected free cash flow to the firm through 2025 and assuming a 10% discount rate and 3% terminal growth rate. Using the average of the two methods, we arrive at a 12-month price target of $3.87 per share, which we round to $4.00." (1/14/2019) Has Alphatec been receiving favorable news coverage? News headlines about ATEC stock have been trending somewhat positive on Sunday, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alphatec earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news stories about the medical technology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are some of Alphatec's key competitors? Some companies that are related to Alphatec include SI-Bone (SIBN), Anika Therapeutics (ANIK), Accuray (ARAY), GenMark Diagnostics (GNMK), MiMedx Group (MDXG), Pulse Biosciences (PLSE), Vapotherm (VAPO), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), Iradimed (IRMD), Neuronetics (STIM), SeaSpine (SPNE), Westaim (WEDXF), Apyx Medical (APYX) and Cytosorbents (CTSO). What other stocks do shareholders of Alphatec own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alphatec investors own include Macrocure (MCUR), LinnCo (LNCOQ), California Resources (CRC), Great Basin Scientific (GBSN), Catalyst Pharmaceuticals (CPRX), Athersys (ATHX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Viking Therapeutics (VKTX) and Progenics Pharmaceuticals (PGNX). Who are Alphatec's key executives? Alphatec's management team includes the folowing people: Mr. Patrick S. Miles, Exec. Chairman & CEO (Age 53)Mr. Craig E. Hunsaker, Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel (Age 55)Mr. Terry M. Rich, Consultant (Age 51)Mr. Jeffrey P. Rydin, Director (Age 52)Mr. Jeffrey G. Black, Exec. VP & CFO (Age 50) Who are Alphatec's major shareholders? Alphatec's stock is owned by many different of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (1.04%), Stonepine Capital Management LLC (0.78%), Dimensional Fund Advisors LP (0.22%), Dimensional Fund Advisors LP (0.22%), Royce & Associates LP (0.08%) and Raymond James Financial Services Advisors Inc. (0.07%). Company insiders that own Alphatec stock include Brian Snider, Evan Bakst, Jeffrey G Black, Kelli Mari Howell and Terry Rich. View Institutional Ownership Trends for Alphatec. Which major investors are selling Alphatec stock? ATEC stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and Broadfin Capital LLC. View Insider Buying and Selling for Alphatec. Which major investors are buying Alphatec stock? ATEC stock was purchased by a variety of institutional investors in the last quarter, including Suntrust Banks Inc., Royce & Associates LP, Beacon Pointe Wealth Advisors LLC, Raymond James Financial Services Advisors Inc., Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have bought Alphatec stock in the last two years include Brian Snider, Evan Bakst, Jeffrey G Black, Kelli Mari Howell and Terry Rich. View Insider Buying and Selling for Alphatec. How do I buy shares of Alphatec? Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Alphatec's stock price today? One share of ATEC stock can currently be purchased for approximately $2.64. How big of a company is Alphatec? Alphatec has a market capitalization of $114.07 million and generates $91.69 million in revenue each year. The medical technology company earns $-42,460,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Alphatec employs 138 workers across the globe. What is Alphatec's official website? The official website for Alphatec is http://www.alphatecspine.com. How can I contact Alphatec? Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at 760-431-9286 or via email at [email protected] MarketBeat Community Rating for Alphatec (NASDAQ ATEC)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 205 (Vote Underperform)Total Votes: 394MarketBeat's community ratings are surveys of what our community members think about Alphatec and other stocks. Vote "Outperform" if you believe ATEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATEC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: Dividend Stocks - Are They Right For You?